← Back to Clinical Trials
Recruiting NCT07472426

NCT07472426 Effects of Creatine Supplementation on Cognitive Measures and Markers of Acute Kidney Injury After Exercise in the Heat

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07472426
Status Recruiting
Phase
Sponsor University of Northern Iowa
Condition Acute Kidney Injury
Study Type INTERVENTIONAL
Enrollment 20 participants
Start Date 2026-03-12
Primary Completion 2027-03

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 45 Years
Study Type INTERVENTIONAL
Interventions
Creatine MonohydrateMaltodextrin (Placebo)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 20 participants in total. It began in 2026-03-12 with a primary completion date of 2027-03.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this clinical trial is to learn if one week of creatine monohydrate supplementation alters inflammation, markers of acute kidney injury (AKI) risk, and cognitive performance in active, young, healthy volunteers. The main questions it aims to answer are: 1. Does one-week of creatine supplementation alter urinary markers of inflammation (cytokines) during exercise in the heat when compared to placebo? 2. Does one-week of creatine supplementation alter markers of AKI during exercise in the heat when compared to placebo? 3. Does one-week of creatine supplementation attenuate reductions in cognitive measures as a response of fatigue from exertional heat stress. Researchers will compare creatine monohydrate to a placebo (maltodextrin) to see if it alters inflammation, risk of acute kidney injury, and cognition after exercise in the heat. Participants will : * Complete a baseline aerobic exercise test to measure VO2max * Ingest 20 grams per day of creatine monohydrate or placebo (maltodextrin) for seven consecutive days * Cycle for 90 minutes in a heated chamber (38 C, \~40% relative humidity), alternating low- and high-intensity exercise * Self-collect urine before, after, and one-hour after exercise * Self-insert a rectal thermistor to measure core temperature * Complete cognitive tasks using the NIH toolbox before and after exercise to assess cognition * Complete the other condition (placebo or creatine) at least 21 days later

Eligibility Criteria

Inclusion Criteria: * Age range: 18-45 years old * Physical Activity Level: Classified as 'active' using the criteria of engaging in planned exercise at least 3x/week, for a minimum of 30 minutes per session, over the past 3 months * Aerobic Fitness Level: Subjects must have an aerobic fitness classification of at least 'good' per American College of Sports Medicine (ACSM) criteria and assessed via maximal oxygen uptake test * Health Status: Free of any known cardiovascular, metabolic, renal, or neurologic conditions. * Physical Limitations: Indicates no physical limitations to cycling for \~ 90 minutes * Supplementation: Reports no use of creatine within the past 4 weeks * Recent Illness: Reports no presence of illness, vomiting, or diarrhea in the previous three days. Exclusion Criteria: * Known allergy to creatine or maltodextrin. * History of adverse heat-related events (e.g., heat exhaustion, heat stroke, severe dehydration requiring medical intervention) * Reports use of medications or supplements that may interfere with thermoregulation, heart rate, kidney injury or blood pressure responses during exercise (e.g. NSAID)

Contact & Investigator

Central Contact

Assistant Professor, PhD

✉ jonathan.specht@uni.edu

📞 5635137807

Frequently Asked Questions

Who can join the NCT07472426 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 45 Years, studying Acute Kidney Injury. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07472426 currently recruiting?

Yes, NCT07472426 is actively recruiting participants. Contact the research team at jonathan.specht@uni.edu for enrollment information.

Where is the NCT07472426 trial being conducted?

This trial is being conducted at Cedar Falls, United States.

Who is sponsoring the NCT07472426 clinical trial?

NCT07472426 is sponsored by University of Northern Iowa. The trial plans to enroll 20 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology